In recent months, BioNTech has moved further beyond its COVID-19 roots by acquiring Chinese startup Biotheseus and inking a major Bristol Myers partnership around oncology candidate BNT327, which ...

BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...

Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug after two new cancer cases emerged. | Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug ...

BioNTech SE will showcase data from its oncology pipeline at the AACR Annual Meeting in Chicago from April 25-30, 2025. The presentations will highlight advancements in mRNA cancer immunotherapies, ...

MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer ...

The world could be only a few years away from a cancer vaccine, according to the couple behind the Pfizer/BioNtech COVID-19 vaccine. "We feel that a cure for cancer or to changing cancer patients' ...

Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to take on the dominance of MSD’s Keytruda (pembrolizumab) in solid tumour ...

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings together ...

Add Yahoo as a preferred source to see more of our stories on Google. The logo of BioNTech is pictured at Biontech's research laboratory for individualised vaccines against cancer in Mainz, Germany, ...

Bristol Myers Squibb and BioNTech announced a strategic partnership June 2 to co-develop and co-commercialize BioNTech’s next-generation cancer immunotherapy – BNT327 – across numerous solid tumor ...

We came across a bullish thesis on BioNTech SE on Memyselfandi007’s Substack. In this article, we will summarize the bulls’ thesis on BNTX. BioNTech SE’s share was trading at $103.80 as of March 4th.

BioNTech SE's stock saw a spike in September due to positive data from Summit Therapeutics' ivonescimab, which has a similar mechanism to BioNTech's BNT327. BioNTech's Q3 earnings showed improved ...